Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HK1 | P19367 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171825 | 0.84 | CASP3 (0.35) | CASP3PTGDR2HTR2CALDH1A1LMNA | |
| SCHEMBL2171085 | 0.83 | CASP3 (0.39) | CASP3PTGDR2GAAALDH1A1KDM4E | |
| SCHEMBL2171587 | 0.82 | GAA (0.39) | CASP3PTGDR2GAAALDH1A1KDM4E | |
| SCHEMBL709958 | 0.82 | PTGDR2 (0.45) | CASP3PTGDR2ALDH1A1KDM4EGLA | |
| SCHEMBL2174257 | 0.81 | CASP3 (0.37) | CASP3PTGDR2GAAALDH1A1KDM4E | |
| SCHEMBL27828528 | 0.81 | PTGS2 (0.35) | PTGDR2HTR2CALDH1A1KDM4EMAPT | |
| SCHEMBL11470610 | 0.77 | ALDH1A1 (0.42) | CASP3GAAALDH1A1KDM4EGLA | |
| SCHEMBL2173913 | 0.74 | PTGDR2 (0.42) | PTGDR2 | |
| SCHEMBL2335826 | 0.72 | PTGDR2 (0.46) | CASP3PTGDR2 | |
| SCHEMBL2171906 | 0.72 | HSP90AB1 (0.50) | CASP3GAAALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2346819-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | CASP3 4683/4885PTGDR2 49/4885HTR2C 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.